$4.18
Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
Overview
52-week range
$3.53
$5.36
36% of range
Avg surprise (last 2)
-22.4%
Avg reaction (last 2)
-1.9%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.45 | $-0.38 | -18.4% | +10.0% | -2.2% | earnings |
| Mon Aug 25, 2025 | Jun/2025 | $-0.67 | $-0.53 | -26.4% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.50 | — | — | — | -1.5% | earnings |
Implied volatility — last 90 days
No IV snapshots yet for MOLN.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.